Compare iShares MSCI France ETF (EWQ) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI France ETF vs Organon & Co. Common Stock — how do they compare? iShares MSCI France ETF trades at $41.52 (market cap $330.41M), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Organon & Co. Common Stock is far larger — about 11× iShares MSCI France ETF's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while iShares MSCI France ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI France ETF for 57 Days and Organon & Co. Common Stock for 0 Days on average.
| EWQ | OGN | |
|---|---|---|
Market Cap | $330.41M | $3.62B |
Volume | 244,426 | 2,892,999 |
Sector | Broad Market / Factor | Health |
52-Week High | $48.35 | $13.81 |
52-Week Low | $41.24 | $5.70 |
Typical Hold Time | 57 Days | 0 Days |
Enterprise Value | — | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWQ is trading at $41.63, up 0.95% with a bearish technical signal from moving averages. The stock faces European market pressures including ECB rate hikes and energy-driven inflation concerns. Key support sits at $41 with resistance at $42, while RSI indicators show mixed signals between neutral and oversold conditions.
European economic uncertainty and monetary tightening create headwinds, though Goldman Sachs notes resilience in European equities. The stock's technical weakness suggests cautious near-term positioning amid macroeconomic volatility in eurozone markets.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares MSCI France ETF
EWQ is a country-specific ETF that tracks the performance of the French equity market. It provides exposure to major global brands across sectors like luxury goods, industrials, and healthcare, including LVMH, Schneider Electric, and Hermes.
Read more on EWQ →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
